Ginsenoside Rd(Synonyms: 人参皂苷 Rd; Gypenoside VIII)

天然产物 糖类和糖苷 Saccharides and Glycosides

Ginsenoside Rd;(Synonyms: 人参皂苷 Rd; Gypenoside VIII) 纯度: 98.02%

Ginsenoside Rd 抑制 TNFα 诱导的 NF-κB 转录活性,IC50 为 12.05±0.82 μM。Ginsenoside Rd 抑制 COX-2iNOS mRNA 的表达。Ginsenoside Rd 还抑制 Ca2+ 内流。Ginsenoside Rd 抑制CYP2D6CYP1A2CYP3A4CYP2C9IC50 分别为 58.0±4.5 μM,78.4±5.3 μM,81.7±2.6 μM 和 85.1±9.1 μM。

Ginsenoside Rd(Synonyms: 人参皂苷 Rd; Gypenoside VIII)

Ginsenoside Rd Chemical Structure

CAS No. : 52705-93-8

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥1250 In-stock
5 mg ¥700 In-stock
10 mg ¥1200 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Ginsenoside Rd 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Metabolism/Protease Compound Library
  • Neuronal Signaling Compound Library
  • NF-kappa;B Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Glycoside Compound Library
  • Lipid Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Pyroptosis Compound Library
  • Traditional Chinese Medicine Monomer Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

IC50 Target

NF-κB

12.05 mu;M (IC50, in HepG2 cells)

COX-2

;

L-type calcium channel

;

CYP2D6

58 mu;M (IC50)

CYP1A2

78.4 mu;M (IC50)

CYP3A4

81.7 mu;M (IC50)

CYP2C9

85.1 mu;M (IC50)

Human Endogenous Metabolite

;

体外研究
(In Vitro)

Ginsenoside Rd is one of the most abundant ingredients of Panax ginseng. Ginsenoside Rd significantly inhibits TNF-α-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 in HepG2 cells. Ginsenoside Rd also inhibits expression of COX-2 and iNOS mRNA and iNOS promoter activity in a dose-dependent manner. To determine nontoxic concentrations, HepG2 cells are treated with various concentrations (0.1, 1, and 10 μM) of compounds (e.g., Ginsenoside Rd) and cell viability is measured using an MTS assay. No compounds are significantly cytotoxic at up to 10 μM, indicating that NF-κB inhibition is not due to cell toxicity[1]. Ginsenoside Rd is one of the most abundant ingredients of Panax ginseng, protects the heart via multiple mechanisms including the inhibition of Ca2+ influx. Ginsenoside Rd reduces ICa,L peak amplitude in a concentration-dependent manner (IC50=32.4±7.1 μM)[2]. Ginsenoside Rd exhibits an inhibition against the activity of CYP2D6 in human liver microsomes with an IC50 of 58.0±4.5 μM, a weak inhibition against the activity of CYP1A2, CYP3A4, and CYP2C9 in human liver microsomes with IC50s of 78.4±5.3, 81.7±2.6, and 85.1±9.1, respectively, and an even weaker inhibition against the activity of CYP2A6 in human liver microsomes with an IC50 value of more than 100 μM[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Ginsenosides Rd is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in ApcMin/+ mice. Six-weeks-old mice are subjected to Ginsenoside Rd treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/ Ginsenoside Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Ginsenoside Rd treatments[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

947.15

Formula

C48H82O18

CAS 号

52705-93-8

中文名称

人参皂苷 Rd

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20deg;C 3 years
4deg;C 2 years
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : 100 mg/mL (105.58 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0558 mL 5.2790 mL 10.5580 mL
5 mM 0.2112 mL 1.0558 mL 2.1116 mL
10 mM 0.1056 mL 0.5279 mL 1.0558 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52.

    [2]. Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64.

    [3]. Lu C, et al. Inhibition of L-type Ca2+ current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77.

    [4]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in ApcMin/+ mice. Sci Rep. 2017 Oct 2;7(1):12552.

Cell Assay
[1]

An MTS assay is used to analyze the effects of the compounds on cell viability. HepG2 cells are cultured overnight in a 96-well plate (1×104 cells/well). Cell viability is assessed after adding the compounds (e.g., Ginsenoside Rd; 0.1, 1, and 10 μM) for 24 h. The number of viable cells is determined by the A490nm of the dissolved formazan product, after addition of MTS for 30 min[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Mice[3]
Heterozygous male ApcMin/+ (C57BL/6J-ApcMin/+) mice are used. Total 32 male ApcMin/+ mice (aged 6 weeks) are divided into three groups; 10 mice in the control group and 22 mice equally divided for Rb3 and Rd treatments. The mice are daily gavage with a single dose of Ginsenoside Rb3 or Ginsenoside Rd at 20 mg/kg, or solvent control. The treatments are carried out for 8 consecutive weeks.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52.

    [2]. Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64.

    [3]. Lu C, et al. Inhibition of L-type Ca2+ current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77.

    [4]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in ApcMin/+ mice. Sci Rep. 2017 Oct 2;7(1):12552.

Ginsenoside Rd2(Synonyms: 人参皂苷RD2)

天然产物 糖类和糖苷 Saccharides and Glycosides

Ginsenoside Rd2;(Synonyms: 人参皂苷RD2) 纯度: 99.55%

Ginsenoside Rd2 是在人参中发现的一种具有抗炎作用的皂苷。

Ginsenoside Rd2(Synonyms: 人参皂苷RD2)

Ginsenoside Rd2 Chemical Structure

CAS No. : 83480-64-2

规格 价格 是否有货 数量
1 mg ¥2300 In-stock
5 mg ; 询价 ;
10 mg ; 询价 ;

* Please select Quantity before adding items.

Ginsenoside Rd2 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus

生物活性

Ginsenoside Rd2 is a saponin found in Panax japonicus with anti-inflammatory actions[1].

分子量

917.13

Formula

C47H80O17

CAS 号

83480-64-2

中文名称

人参皂苷RD2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4deg;C, protect from light

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light)

参考文献
  • [1]. Li-Juan Ma, et al. Comparative study on chemical components and anti-inflammatory effects of Panax notoginseng flower extracted by water and methanol. J Sep Sci. 2017 Dec;40(24):4730-4739.

StemRNA 3rd Gen Reprogramming Kit StemRNA第三代重编程试剂盒

StemRNA 3rd Gen Reprogramming Kit
StemRNA第三代重编程试剂盒

  • 产品特性
  • 相关资料
  • Q&A
  • 参考文献

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒

StemRNA 3rd Gen Reprogramming Kit

StemRNA第三代重编程试剂盒 (又名StemRNA™-NM重编程试剂盒)


Stemgent RNA重编程的新产品——StemRNA第三代重编程试剂盒(旧名StemRNA-NM重编程试剂盒),结合了未经修饰的RNA和microRNA技术,使干细胞研究人员追求的多功能性、简易性和时间效益提升到一个新的层次,使人成纤维细胞,以及来自难以重编程的患者血液和尿液的细胞样品得已重编程,成为具有全能性的诱导型多功能干细胞(iPS)。


◆主要优点

● 运用灵活技术,可从多种靶细胞得到高质量的人iPS细胞系

● 即开即用。可用于来自皮肤(成纤维细胞),血液(内皮祖细胞; EPCs)和尿液(尿源性上皮细胞; UDCs)细胞的重编程。


● 高效率的非整合重编程

● StemRNA-3rd Gen仅需要少至四种额外的试剂。试剂盒中的双链microRNA可增强重编程效率,提高iPS获得效率(成纤维细胞高达4%,EPC高达3%,UPC高达0.5%)。


● 省时的操作更快获得结果,从而提高吞吐量

● 从成纤维细胞的细胞系中得到iPS克隆需要10-14天,而从EPC或UPC中获得细胞系需要12-16天。无需筛选,无需像其他技术般额外培养2-10周(3-10代)以清除载体。

 

StemRNA 3rd Gen Reprogramming Kit (00-0076)

特点

成纤维细胞

尿液 (UDCs)

血液(EPCs)

每个试剂盒可转染的孔数(6孔板)

9

3

3

转染次数

4

6-8

6-8

获得原代iPS细胞克隆所需天数

10-14

12-14

12-14

重编程效率

2-+4%

0.1-0.5%

0.4-3%

筛选

兼容异源成分的培养步骤

GMP级的RNA制备步骤

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒


在NutriStem™ XF / FF培养基(01-0005)中扩增后,使用StainAlive™ TRA-1-60抗体(09-0068)和DAPI对UDCs的P7原代iPS细胞进行染色。

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒


StemRNA 3rd Gen Reprogramming Kit

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒

以StemRNA 3rd Gen Reprogramming Kit 配合NutriStem™ XF/FF培养基(01-0005)及iMatrix-511(NP892-011)基质上培养成纤维细胞衍生的iPS细胞7代。 放大倍数:4x

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒


StemRNA-NM的成纤维细胞重编程s时间表



◆产品说明


规格

 1 kit

试剂盒组分

 OKSMNL NM-RNA(编号05-0040),30 µg,1 vial
 EKB NM-RNA(编号05-0041),22 µg,1 vial
 NM-microRNAs(编号05-0042),15 µg,1 vial

储存与稳定性

 1. 试剂盒三种成分均需储存在-70°C以下;
 2. 在适当的保存条件下,自到货后三个月内有效。

质量控制

 试剂盒种每种mRNA的大小与完整性均经过检测。

 StemRNA 3rd Gen Reprogramming Kit 成功进行了人成纤维细胞和人脐静脉内皮细胞RNA基础重编程功能验证。

 iPS细胞系完全重编程可通过多能性标记物的表达及正确的形态来确认。

 试剂盒所有组分均无菌,支原体检测均呈阴性。

使用许可

 该产品使用Biontech AG独家许可技术,引自专利WO 2009/088134。

 Biontech AG的WO 2007/036366,WO 2007/036366,WO 2007/036366和WO 2007/036366等多专利也涵盖

 了本产品。

◆产品列表


产品编号

产品名称

规格

00-0076

Stemgent® StemRNA™ 3rd Generation Reprogramming Kit
    (StemRNA-NM Reprogramming Kit)

1 kit

◆相关产品

 产品编号

产品名称

包装

01-0005

NutriStem XF/FF Culture Medium (500 mL)
NutriStem 无饲养层干细胞培养基

500 mL

01-0005-100

NutriStem XF/FF Culture Medium (100 mL)

NutriStem 无饲养层干细胞培养基

100 mL

03-0002

Stemfactor™ FGF-Basic, Human Recombinant
Stemfactor™ FGF-Basic,人重组

50 µg

01-0020-50

NutriFreez D10 Cryopreservation Mediu

50 mL

iMatrix-511


产品编号

产品名称

包装

NP892-011

iMatrix-511
iMatrix-511层粘连蛋白

350 μg

NP892-012

1050 μg

NP892-013

175 μg

385-07361

iMatrix-511 solution(0.5 mg/mL)
重组层粘连蛋白511-E8片段,溶液(0.5 mg/mL)

175 μg×2


iMatrix-511产品详细信息请点击:iMatrix-511层粘连蛋白


查看相关产品宣传册,请点击:Stemgent细胞重编程

相关资料



◆视频

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒

Stemgent mRNA 重编程试剂盒使用技巧

◆宣传页以及说明书


StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒

Stemgent_RNA Reprogramming System

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒

血液-Protocol

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒

尿液-Protocol

StemRNA 3rd Gen Reprogramming Kit                               StemRNA第三代重编程试剂盒

成纤维细胞-Protocol

参考文献

1. 

Poleganov MA; Eminli S; Beissert T; Herz S; Moon J-I; Goldmann J; Beyer A; Heck R; Burkhart I; Roldan DB; Tureci O; Yi K; Hamilton B; Sahin U. "Efficient reprogramming of human fibroblasts and blood-derived endothelial progenitor cells using nonmodified RNA for reprogramming and immune evasion." Human Gene Therapy 26:751 (2015)



Featured Publication


2.

Gagliano O; Luni C; Qui W; Bertin E; Torchio E; Galvanin S; Urciuolo A; Elvassore N. Microfluidic reprogramming to pluripotency of human somatic cells. Nat. Protocols 14:772-737 (2019).

 

The StemRNA 3rd Gen Reprogramming Kit was used to generate iPSCs from fibroblasts in a microfluidic system that used only 1500 cells in 20 µL of medium. RNA-based reprogramming is ideal for such an application since it does not require extended culture for elimination of reprogramming vectors.



Additional Publications


3.

Nakajima M; Yoshimatsu S; Sato T; Nakamura M; Okahara J; Sasaki E; Shiozawa S; Okano H. Establishment of induced pluripotent stem cells from common marmoset fibroblasts by RNA-based reprogramming. Biochem Biophys Research Commun in press:

https://doi.org/10.1016/j.bbrc.2019.05.175 (2019).

4.

Watanabe T; Yamazaki S; Yoneda N; Shinohara H; Tomioka I; Iiguchi T; Tagoto M; Ema M; Suemizu H; Kawai K; Sasaki E. Highly efficient induction of primate iPS cells by combining RNA transfection and chemical compounds. Genes to Cells in press:doi:10.1111/gtc.12702 (2019).

5.

Liu L-P; Li Y-M; Guo N-N; LI S; Ma X; Zhang Y-X; Gao Y; Huang J-L; Zheng D-X; Wang L-Y; Xu H; Hui L; Zheng Y-W. Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation. Cell Reports 27:455-466.e5 (2019).

6.

Sacco AM; Belviso I; Romano V; Carfora A; Schonauer F; Nurzynska D; Montagnani S; Di Meglio F; Castaldo C. Diversity of dermal fibroblasts as major determinant of variability in cell reprogramming. J Cell Mol Med :1-13; https://doi.org/10.1111/jcmm.14316 (2019).

7.

Klein T; Klug K; Henkel L; Kwok CK; Edenhofer F; Klopocki E; Kurth I; Üceyler N. Generation of two induced pluripotent stem cell lines from skin fibroblasts of sisters carrying a c.1094C>A variation in the SCN10A gene potentially associated with small fiber neuropathy. Stem Cell Res 35:101396 (2019).

8.

Dasgupta B; Rusha E; Drukker M. iPSC generation, prime to naïve reversion & characterization and primordial germ cell differentiation of Northern White Rhino. Univ Bremen : (2019).

9.

Su S; Guntur AR; Nguyen DC; Fakory SS; Doucette CC; Leech C; Lotana H; Kelley M; Kohil J; Martino J; Sims-Lucas S; Liaw L; Vary C; Rosen CJ; Brown AC. A Renewable Source of Human Beige Adipocytes for Development of Therapies to Treat Metabolic Syndrome. Cell Reports 25:3215-3228.e9 (2018).

10.

Klein T; Henkel L; Klug K; Kwok CK; Klopocki E; Üceyler N. Generation of the human induced pluripotent stem cell line UKWNLi002-A from dermal fibroblasts of a woman with a heterozygous c.608 C>T (p.Thr203Met) mutation in exon 3 of the nerve growth factor gene potentially associated with hereditary sensory and autonomic neuropathy type 5. Stem Cell Research

https://doi.org/10.1016/j.scr.2018.10.017 (2018)

11.

Liu X; Nefzger CM; Rossello FH; Chen J; Knaupp AS; Firas J; Ford E; Pflueger J; Paynter JM; Chy HS; O'Brien CM; Huang C; Mishra K; Hodgson-Garms M; Jansz N; Williams SM; Blewitt ME; Nilsson SK; Schittenhelm RL; Laslett AL; Lister R; Polo JM. Comprehensive characterization of distinct states of human naive pluripotency generated by reprogramming. Nature Methods 14:1055 (2017)


产品列表
产品编号 产品名称 产品规格 产品等级 备注
00-0076 StemRNA™-NM Reprogramming Kit
StemgentRNA™-NM重编程试剂盒
1 kit

天光RD-1熔点测试仪

天光RD-1熔点测试仪

天光RD-1熔点测试仪

产品编号:
市场价:¥0.00
会员价:¥0.00
品牌:天光
生产厂家:天光

  • 产品概览
  • 技术参数
  • 订购信息
  • 相关资料
  • 相关产品

天光RD-1熔点测试仪

熔点是指物质由固态变为液态时的温度,是测定物质及其纯度的重要方法之一。

 ·熔点测试仪用于检查药物、香料、染料及其它晶体物质的熔点。

主要特点

 ·高精度温度传感器测量温度,自动修正非线性误差。

 ·自动变频控制技术,温度控制精确度高,升温速率线性误差小。

 ·自动储存记录预置值和熔点值,断电不丢失。

测试范围: 室温~270℃

 ·测试精度: <200℃时 ≯±0.5℃

        ≥200℃时 ≯±1.0℃

 ·环境温度: 15~35℃

 ·温度范围: 50~260℃

 ·传温介质: 甲基硅油

 ·传温液杯: 250ml高型烧杯

 ·升温速率: 0.5、1.0、1.5、3.0℃/min

 ·升温精度: ≤10%

 ·加热功率: 200W

 ·电  源: 220V/50Hz/500W

 ·外型尺寸: 320×180×290mm3

LPS from S. minnesota R7 (Rd1) TLRpure Sterile Solution 脂多糖来源于明尼苏达沙门氏菌R7 (Rd1) TLR纯净无菌溶液 品牌:Innaxon


LPS from S. minnesota R7 (Rd1) TLRpure Sterile Solution

脂多糖来源于明尼苏达沙门氏菌R7 (Rd1) TLR纯净无菌溶液

品牌:Innaxon
CAS No.:
储存条件:+4°C
纯度:>99.9%. No detectable DNA, RNA and protein traces.
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

IAX-100-018-C500

500 µg 1,810.00


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

LPS from S. minnesota R7 (Rd1) TLRpure Sterile Solution 脂多糖来源于明尼苏达沙门氏菌R7 (Rd1) TLR纯净无菌溶液 品牌:Innaxon


LPS from S. minnesota R7 (Rd1) TLRpure Sterile Solution

脂多糖来源于明尼苏达沙门氏菌R7 (Rd1) TLR纯净无菌溶液

品牌:Innaxon
CAS No.:
储存条件:+4°C
纯度:>99.9%. No detectable DNA, RNA and protein traces.
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

IAX-100-018-M001

1 mg 2,770.00


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

LPS from S. minnesota R3 (Rd2) TLRpure Sterile Solution 脂多糖来源于明尼苏达沙门氏菌R3 (Rd2) TLR纯净无菌溶液 品牌:Innaxon


LPS from S. minnesota R3 (Rd2) TLRpure Sterile Solution

脂多糖来源于明尼苏达沙门氏菌R3 (Rd2) TLR纯净无菌溶液

品牌:Innaxon
CAS No.:
储存条件:+4°C
纯度:>99.9%. No detectable DNA, RNA and protein traces.
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

IAX-100-021-C500

500 µg 1,810.00


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

LPS from S. minnesota R3 (Rd2) TLRpure Sterile Solution 脂多糖来源于明尼苏达沙门氏菌R3 (Rd2) TLR纯净无菌溶液 品牌:Innaxon


LPS from S. minnesota R3 (Rd2) TLRpure Sterile Solution

脂多糖来源于明尼苏达沙门氏菌R3 (Rd2) TLR纯净无菌溶液

品牌:Innaxon
CAS No.:
储存条件:+4°C
纯度:>99.9%. No detectable DNA, RNA and protein traces.
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

IAX-100-021-M001

1 mg 2,770.00


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

LPS from S. minnesota R7 (Rd1) TLRpure Sterile Solution 脂多糖来源于明尼苏达沙门氏菌R7 (Rd1) TLR纯净无菌溶液 品牌:Innaxon


LPS from S. minnesota R7 (Rd1) TLRpure Sterile Solution

脂多糖来源于明尼苏达沙门氏菌R7 (Rd1) TLR纯净无菌溶液

品牌:Innaxon
CAS No.:
储存条件:+4℃
纯度:≥99.9%
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

IAX-100-018-5001

5×1 mg

LPS from S. minnesota R7 (Rd1) TLRpure Sterile Solution                                                      脂多糖来源于明尼苏达沙门氏菌R7 (Rd1)  TLR纯净无菌溶液            品牌:Innaxon


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

LPS from S. minnesota R3 (Rd2) TLRpure Sterile Solution 脂多糖来源于明尼苏达沙门氏菌R3 (Rd2) TLR纯净无菌溶液 品牌:Innaxon


LPS from S. minnesota R3 (Rd2) TLRpure Sterile Solution

脂多糖来源于明尼苏达沙门氏菌R3 (Rd2) TLR纯净无菌溶液

品牌:Innaxon
CAS No.:
储存条件:+4℃
纯度:≥99.9%
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

IAX-100-021-5001

5×1 mg

LPS from S. minnesota R3 (Rd2) TLRpure Sterile Solution                                                      脂多糖来源于明尼苏达沙门氏菌R3 (Rd2)   TLR纯净无菌溶液            品牌:Innaxon


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。